Stem cell labs disrupted by judge's order

Labs engaged in embryonic stem cell research are scrambling this morning as they attempt to deal with the unexpected fall-out of a federal judge's ruling that President Barack Obama's executive order expanding the reach of the government's support for the field violated an earlier presidential ban on funding. "This ruling means an immediate disruption of dozens of labs doing this work since the Obama administration made its order," stem cell scientist George Daley tells The New York Times. Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.